Introduction
The FDA has granted approval for rusfertide (Mimrylo), the first-in-class medication designed to treat erythrocytosis in adults suffering from polycythemia vera (PV), a rare and slow-developing hematological malignancy.
Mechanism of Action
Rusfertide functions by mimicking hepcidin, a natural hormone that regulates iron levels in the body. Controlling hematocrit levels is essential in managing PV, as elevated hematocrit increases the risk of severe cardiovascular events like blood clots, strokes, or heart attacks.
Clinical Trials
The approval stems from the positive outcomes of the VERIFY phase III trial, which demonstrated that rusfertide reduces the need for phlebotomy in PV patients with uncontrolled hematocrit levels despite standard therapies.
Dr. Andrew Kuykendall from the Moffitt Cancer Center noted that existing treatments, particularly phlebotomy, often leave significant gaps for many patients, impacting their daily lives. The introduction of Mimrylo provides healthcare professionals and patients with a novel therapeutic option that addresses erythrocytosis, a core issue in PV management.
Trial Results
In the VERIFY trial, participants were randomized to receive standard care plus either subcutaneous rusfertide—adjusted to maintain hematocrit levels below 45%—or a matching placebo. The findings revealed that a significantly higher percentage of patients treated with rusfertide required no phlebotomy during weeks 20 to 32 compared to the placebo group (76.9% vs 32.9%, P<0.001). Additionally, those in the rusfertide group averaged fewer phlebotomies over 32 weeks (0.5 vs 1.8, P<0.0001).
Safety Profile
The most common adverse events associated with rusfertide included injection-site reactions (56%) and anemia (16%). It is important to be aware of potential warnings in the drug’s labeling, which indicate risks for new or worsening thrombocytosis, injection-site reactions, and embryo-fetal toxicity.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional for personal medical guidance.
Fuente: https://www.medpagetoday.com/hematologyoncology/hematology/122831
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
